Related Experiment Video
Updated: Jun 25, 2025
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma
Jelisah F Desgraves1, Mynor J Mendez Valdez1, Jay Chandar1
1Section of Virology and Immunotherapy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Purpose:
The limited efficacy of current treatments for malignant brain tumors necessitates novel therapeutic strategies. This study aimed to assess the potential of antisense oligonucleotides (ASOs) as adjuvant therapy for high-grade gliomas, focusing on their CNS penetration and clinical translation prospects.
Methods:
A comprehensive review of the existing literature was conducted to evaluate the implications of ASOs in neuro-oncology. Studies that investigated ASO therapy's efficacy, CNS penetration, and safety profile were analyzed to assess its potential as a therapeutic intervention for high-grade gliomas.
Results:
ASOs present a promising avenue for enhancing targeted gene therapies in malignant gliomas. Their potent CNS penetration, in vivo durability, and efficient transduction offer advantages over conventional treatments. Preliminary in vivo and in vitro studies suggest ASOs as a viable adjuvant therapy for high-grade gliomas, warranting further exploration in clinical trials.
Conclusions:
ASOs hold significant promise as adjuvant therapy for high-grade gliomas, offering improved CNS penetration and durability compared with existing treatments. While preliminary studies are encouraging, additional research is needed to establish the safety and efficacy of ASO therapy in clinical settings. Further investigation and clinical trials are warranted to validate ASOs as a transformative approach in neuro-oncology.
Insights
Antisense oligonucleotides (ASOs) show promise as adjuvant therapy for high-grade gliomas, offering better brain penetration and durability. Further clinical trials are needed to confirm their safety and efficacy in treating these malignant brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Therapy
Background:
- Malignant brain tumors, such as high-grade gliomas, have limited treatment options.
- Novel therapeutic strategies are essential to improve patient outcomes.
Purpose of the Study:
- To evaluate antisense oligonucleotides (ASOs) as a potential adjuvant therapy for high-grade gliomas.
- To assess the central nervous system (CNS) penetration and clinical translation prospects of ASOs.
Main Methods:
- A comprehensive literature review was performed.
- Studies on ASO efficacy, CNS penetration, and safety in neuro-oncology were analyzed.
Main Results:
- ASOs demonstrate potent CNS penetration, in vivo durability, and efficient transduction.
- Preliminary studies suggest ASOs are a viable adjuvant therapy for malignant gliomas.
- ASOs offer advantages over conventional treatments for brain tumors.
Conclusions:
- ASOs hold significant promise for treating high-grade gliomas.
- Further research and clinical trials are necessary to establish the safety and efficacy of ASO therapy.
- ASOs may represent a transformative approach in neuro-oncology.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:28Leaky Scanning
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
00:59Gene Therapy